TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
TG THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$53.30−0.67 (-1.24%)
Close on Oct 19, 2026
- Market cap
- $8.38B
- P/E (TTM)
- 19.5
- Dividend yield
- –
Share price
+$18.63 (+53.74%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
TG THERAPEUTICS, INC. grew revenue 76.1% to $799.54M over the twelve months to Jun 30, 2026. Operating income rose 58.8% to $136.33M, moving the operating margin from 18.9% to 17.1%. Free cash flow was $17.39M.
Revenue
$799.54M
+76.1% vs. a year earlier
Operating income
$136.33M
+58.8% vs. a year earlier
Free cash flow
$17.39M
TTM Q2 2026
EPS, diluted
$2.74
+640.5% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $8.38B
- P/E ratio
- 19.5
- Price to sales
- 10.48
- Price to book
- 13.88
- Dividend yield
- –
- Free cash flow yield
- 0.21%
Fundamentals
- Revenue
- $799.54M
- Net income
- $441.49M
- EPS, diluted
- $2.74
- Free cash flow
- $17.39M
- Book value per share
- $3.84
- Diluted shares
- 157M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$799.54M+76.1% YoY
Gross profit
$658.60M+66.8% YoY
Operating income
$136.33M+58.8% YoY
Net income
$441.49M+630.2% YoY
EPS, diluted
$2.74+640.5% YoY
Free cash flow
$17.39M
Reported periodTrailing twelve months